Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

Br J CancerJun 23, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Jiajia Yuan, Jifang Gong, Zhi Peng et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase 2, single-arm trial evaluated the efficacy and safety of infigratinib in 21 patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification. The study found a confirmed objective response rate of 23.8% and a median overall survival of 6.7 months, indicating preliminary antitumor activity in this population.

Key findings

  • Confirmed objective response rate of 23.8% (95% CI, 8.2-47.2).
  • Median progression-free survival was 3.4 months.
  • Median overall survival was 6.7 months.
  • Most common grade 3-4 adverse events included elevated aspartate aminotransferase and neutropenia.

Why it matters

The study highlights the potential of FGFR2 as a therapeutic target in advanced gastric cancer, suggesting that infigratinib may offer a new treatment option for patients with limited alternatives after multiple lines of therapy.

Source

PubMed · PMID 42337043Free full text on PubMed Central

Published in Br J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.